

Hypercoagulable Testing Reduction

Effective Date: October 29, 2025

Agile MD is a software application that allows providers to order tests and consultations using algorithmic pathways. Two AgileMD pathways: “Hypercoagulable Testing, Adult, Inpatient” for ischemic stroke and deep vein thrombosis/pulmonary embolism were developed in order to align inpatient testing with guidelines by the American Society of Hematology and other leading medical organizations. To further align with these guidelines and reduce low-value and unnecessary inpatient testing, several tests used for thrombophilia work ups and antiphospholipid antibody testing will be removed from the inpatient ordering menu*.

Expect emergency department (ED) and inpatient ordering restrictions and the launch of hypercoagulable testing pathways by October 29, 2025.

*The following tests will be removed from ED and inpatient ordering *unless a provider obtains direct approval from a pathologist*.

- Protein C Activity [LAB489]
- Protein S Activity [LAB491]
- Activated protein C resistance [LAB1231059]
- Pathologist Interpretation, Thrombophilia [LAB1231248]
- Factor V Leiden DNA Analysis [LAB346]
- Prothrombin G20210A [LAB8340]
- Factor V Leiden DNA / Prothrombin G20210A [LAB1230857]
- Pathologist Interpretation, Antiphospholipid [LAB1231242]
- DRVVT [LAB1231078]
- Hexagonal Phase Phospholipid [LAB1231139]

For questions and/or special requests for thrombophilia or antiphospholipid testing, please contact the coagulation pathologist via Mobile Heartbeat: Clinical Pathology Provider/Coagulation Royal Oak.

If a pathologist cannot be reached, please contact the coagulation lab: 248-551-8084.

Date submitted: October 21, 2025

Submitted by: Marc Smith, Coagulation Medical Director. Megan Masakowski (MLS), Division Hematology Manager.